share_log

Sarepta Therapeutics shares are trading higher after the company announced new results from the ongoing study of SRP-9003, the company's investigational gene therapy for limb-girdle muscular dystroph

Sarepta Therapeutics shares are trading higher after the company announced new results from the ongoing study of SRP-9003, the company's investigational gene therapy for limb-girdle muscular dystroph

Sarepta Treeutics股价上涨，此前该公司宣布了正在进行的SRP-9003研究的新结果，SRP-9003是该公司针对四肢带状肌营养不良的调查性基因疗法
Benzinga ·  2021/03/19 05:02

Sarepta Therapeutics shares are trading higher after the company announced new results from the ongoing study of SRP-9003, the company's investigational gene therapy for limb-girdle muscular dystrophy Type 2E.

Sarepta治疗公司的股价上涨，此前该公司宣布了正在进行的SRP-9003研究的新结果。SRP-9003是该公司针对2E型肢体带状肌营养不良症的调查性基因疗法。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发